An eculizumab biosimilar for the USA
Global Action has received this notice from the FDA. We cannot find a price or evidence from an aHUS trial as…
An eculizumab biosimilar for USA
Global Action has received this notice from the FDA. Cannot find a price or evidence from an aHUS trial as yet.…
Newsletter: aHUS Global Advocate, 9th Edition
The aHUS Global Advocate Newsletter, highlights of news & views with a focus on the rare disease atypical HUS. Our 9th Edition, March 2024
World Kidney Day 2024 – a webinar
Today is World Kidney Day. An annual awareness day to bring kidney disease matters to the world’s attention. aHUS is a…
What the RDD24 aHUS video tells us.
The Steven Spielberg of aHUS videos (Jeff) has produce another aHUS video for RDD24. Sixty six aHUS patients /carers starred in…
Dr Leonard Bell – Before aHUS Endeavours Fade
Those new to the disease aHUS may not know the significant contribution that Dr Leonard Bell has made to their treatment…
Epidemiology – aHUS Agenda Topic 15-
aHUS epidemiology is the about how many aHUS patients there are. The numbers onsetting and surviving. It’s “Incidence” and “prevalence”. How…
AHUS patients met with FDA and this is what they said
In September last year a group of aHUS patients and parent/carers met with FDA and told them about aHUS. A summary…
aHUS Trials Watch 19- Iptacopan
FDA has approved the use of Iptacopan, brand name Fabhalta, for PNH. Two trials demonstrated that this Factor B complement inhibitor…